Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Investor Presentation (May 2022)
25 slides from Poly Medicure's investor presentation, May 24, 2022
Slide 1: Regulation 30 compliance cover letter to exchanges
Poly Medicure Limited Regd . Office : 232- B, 3'' Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110020 (INDIA) T:+91-ll-33550700,47317000,F: +91-ll-26321894,26321839 P lYMED MEDICAL DEVICES We Care As We Cure E: info@polymedicure.com W: polymedicure.com CIN : L 40300DL l 995PLC066923 Date:
Slide 2: Investors Presentation May 2022
Investors Presentation May 2022 www.polymedicure.com Confidential
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in w
Slide 4: Content
Content Our Journey Board of Directors & Management Corporate Structure Polymed’s Unique Position Five Year Vision Customer Stickiness, Sustainable Business Manufacturing Key Financials and Ratios New Product launches Corporate Communication Way Forward, Capex Update Awards and recognition Confident
Slide 5: Our Journey: Milestone Achievements
OUR JOURNEY…..…..MILESTONE ACHIEVEMENTS 1997 2001 2002 2004 2006 2007 2009 Commencement of Expansion of JV in Egypt Faridabad Plant-2 Acquired 75% of New Plant China Plant Manufacturing Faridabad Plant Extension (100% US Safety Haridwar Operation EOU) Syringes 2011 2014 2016 2018 2020 2021 *2022 *20
Slide 6: Across the world, we serve people in over 120+ countries
ACROSS THE WORLD, WE SERVE PEOPLE IN OVER 120+ COUNTRIES 9 Manufacturing Plants* (*2 under construction) 1 R&D Center UNIQUELY POSITIONED TO PROVIDE VALUE TO OUR CUSTOMERS Confidential I Slide 2
Slide 7: Board of Directors & Management
BOARD OF DIRECTORS & MANAGEMENT Mr. Devendra Raj Mehta (Chairman, Non Executive Independent Director) Mr. Himanshu Baid Mr. Rishi Baid (Managing Director) (Joint Managing Director) Mr. Jugal Kishore Baid Mrs. Mukulika Baid Dr. Shailendra Raj Mehta (Non Executive Director) (Non Executive Director) (N
Slide 8: Corporate Structure
CORPORATE STRUCTURE POLYMED GROUP INDIA OVERSEAS Poly Medicure Poly Medicure BV- Ultra for Medical (Laiyang) Co. Ltd. Netherlands Poly Medicure Ltd Products Co. China Wholly owned (UMIC) – Egypt Holding Co. Wholly owned Subsidiary Associate (23%) Subsidiary (100%) (100%) Plan 1 Health India Pvt. Ltd
Slide 9: Polymed's Unique Position
POLYMED’S UNIQUE POSITION EMINENCE IN FLUID MANAGEMENT DISPOSABLES AND PROCEDURAL MEDICAL DEVICES COMPREHENSIVE PRODUCT RANGE INNOVATION, AN INTEGRAL PART OF POLYMED STORY Oncology Infusion & Vascular Access Amongst the Top 3 I.V. Cannula Manufacturer in the world 1st In India Molecular Diagnostics
Slide 10: 2020-2025 Vision
2020-2025 VISION TRANSFORM FROM A PRODUCT COMPANY TO A SOLUTION PROVIDER ORGANIZATION Started in 1997 2002-2009 2011-2019 2020-2021 2022-2025 2026 and beyond Commencement of Product and facility New R&D Center Focus on commercial Launch differentiated Globally recognized Manufacturing expansion Acq
Slide 11: Stickiness in Customer Base & Sustainable Business
STICKINESS IN CUSTOMER BASE & SUSTAINABLE BUSINESS LEVERAGE OUR (CUSTOMER) INSTALLED BASE AND DISTRIBUTOR NETWORK TO LAUNCH NEW PRODUCTS Polymed Sales By Geography Polymed Sales By Product Category Polymed Brand and OEM Private Label Sales 12% 7% 28% 34% 5% 4% 66% 9% 72% 63% 4% 3% Export India Infus
Slide 12: Manufacturing Across Four Countries
MANUFACTURING ACROSS FOUR COUNTRIES (INDIA, ITALY, EGYPT, CHINA) 1st Medical Device Company from India to have overseas plants. Faridabad Plant, India Haridwar Plant, India IMT Faridabad India Over 275+ Moulding Machines & 900+ Injection Molds More than 200+ automatic Faridabad Plant, India Jaipur P
Slide 13: Our Strength: Consistent all-round growth (Standalone)
OUR STRENGTH: Consistent all-round growth (Standalone) ₹ ₹ ₹ REVENUE (₹ Crs.) EBIDTA (₹ Crs.) PBT (₹ Crs.) PAT (₹ Crs.) 1000.00 879.36 250.00 250.00 200.00 747.38 208.30 212.13 800.00 194.72 146.02 646.16 200.00 160.14 200.00 173.36 129.50 150.00 600.00 150.00 150.00 121.78 92.38 100.00 400.00 100.0
Slide 14: Creating Value for Shareholders
CREATING VALUE FOR SHAREHOLDERS Increasing Shareholders Base Creating Value for Shareholders NO. OF SHAREHOLDERS MARKET CAP IN INR (CRS) 40000 10000 9105.74 33831 9000 7884.74 35000 8000 30000 7000 25000 21531 6000 20000 5000 4000 15000 8574 3000 2056.36 10000 2000 5000 1000 0 0 No of Shareholders M
Slide 15: Ratios
RATIO’S Interest Coverage Debt Service Coverage 70 64.53 8 6.87 60 6 5.55 50 4.61 40 29.58 4 30 20 14.32 2 10 0 0 % % FY 2020 FY 2021 FY 2022 FY 2020 FY 2021 FY 2022 ROCE ROE 30.00% 21.03% 20.00% 17.19% 20.00% 15.49% 14.05% 11.55% 9.96% 10.00% 10.00% 0.00% 0.00% % % FY 2020 FY 2021 FY 2022 FY 2020 F
Slide 16: Performance Standalone/Consolidated
PERFORMANCE STANDALONE/CONSOLIDATED Poly Medicure Ltd 879.36 Standalone in INR Crs 1000.00 Consolidated in INR Crs 923.06 747.38 900.00 1000.00 646.16 800.00 786.20 900.00 700.00 687.24 800.00 600.00 700.00 500.00 400.00 600.00 212.13 208.30 194.72 173.36 160.14 146.02 300.00 500.00 129.50 121.78 92
Slide 17: New Product Launches - FY 22-23
NEW PRODUCT LAUNCHES - FY 22-23 Arterial blood collection syringe ECG- Electrode PICC Line Polyguard + Labside filter Hubber Needle (Blood Bank Side filter ) Bedside Filter (Oncology) Diagnostic Kits Concentrate Disinfectant Midflux PP & PC, and High Flux PP & pc Dialyzer – Dialyzer 1.4, 1.6, 1.8 Re
Slide 18: Production Linked Incentive Scheme (Renal Care)
PRODUCTION LINKED INCENTIVE SCHEME (RENAL CARE) • Polymed got approval under Renal Care Segment for following products ✓ Dialyzer ✓ Dialysis Machine ✓ Peritoneal Dialysis Kit ✓ Bloodline ✓ Fistula ✓ Transducer Protector • Greenfield projects defined under the guidelines to be operational at IMT Plan
Slide 19: Production Linked Incentive Scheme (In Vitro Diagnostic)
PRODUCTION LINKED INCENTIVE SCHEME (IN VITRO DIAGNOSTIC) • Polymed got approval under In Vitro Diagnostic Medical devices for following products • New range of Molecular Chemicals, reagents and diagnostic kits to be added. • Greenfield projects defined under the guidelines to be operational at IMT P
Slide 20: Corporate Communication
CORPORATE COMMUNICATION Media I Industry Events I Webinars| Social Media I Clinical Engagements I Conferences 1 lac + followers on social media 250 posts pushed last year Annual Summit 2022 Confidential I Slide 16
Slide 21: Corporate Communication
CORPORATE COMMUNICATION Media I Industry Events I Webinars| Social Media I Clinical Engagements I Conferences ARAB HEALTH 2022, DUBAI MEDICA 2021, GERMANY Confidential I Slide 17
Slide 22: Way Forward
WAY FORWARD Vascular Access International Strategy • Relationship building with 04 • Transition to MDR corporate chain of hospitals • Improve Brand visibility in • Expand Dealer network 01 International markets Renal Promote Infection • Introduce Indigenous Dialysis Machine 02 05 Prevention and Safe
Slide 23: Capex Update
CAPEX UPDATE • Capex incurred in FY 2021-22 : INR 151.80 Crs • Capex planned for FY 2022-23 : INR 150.00 Crs Confidential I Slide 19
Slide 24: Awards & Recognition
AWARDS & RECOGNITION “India Medical Device Leader of the Year 2021” by Government of India "Export Excellence Award" by PLEXCONCIL as the largest exporter of disposable medical devices Confidential I Slide 20
Slide 25: Thank You
Poly Medicure Limited Thank You Registered Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com Confidential I Slide 21